# Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy

> **NCT00456833** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 248 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** RAD001
- **DRUG:** erlotinib

## Key facts

- **NCT ID:** NCT00456833
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2011-03
- **Final completion:** —
- **Target enrollment:** 248 (ACTUAL)
- **Last updated:** 2020-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00456833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00456833, "Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00456833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*